Uphuhliso lweebhaktheriya zokuxhathisa iziyobisi ezininzi (MDR) kwiminyaka engamashumi amahlanu edlulileyo kukhokelele ekwandeni kophando ekufuneni umgqatswa weziyobisi ukulungisa oku. AMR khupha. Isibulali-zintsholongwane esipheleleyo esenziwe ngokupheleleyo, i-Iboxamycin, sibonelela ngethemba lokunyanga zombini iintsholongwane zeGram-positive kunye ne-Gram-negative ngendlela ye-bacteriostatic..
Iqela leLincosamide le antibiotics equka ngokukodwa i-clindamycin yinto eqhelekileyo ekhuselekileyo antibiotic ifumaneka ngomlomo. I-agent ye-bacteriostatic kwaye yenza ngokuzibophelela kwi-ribosomes yebhaktheriya. I-Lincomycin, eyokuqala antibiotic yeli qela yahlukaniswa iintsholongwane zomhlaba Streptomyces lincolnensis ngo-1963 kwaye isetyenziswe ngokuchasene ne-Gram positive intsholongwane.
I-Clindamycin, i-semi-synthetic version ye-lincomycin ibisetyenziswa kule minyaka ingama-50 idlulileyo njengeyeza lokulwa ne-antibacterial (kunye ne-antimalarial drug), ingakumbi kunyango losulelo lwamazinyo namathambo. Ngenxa yokusetyenziswa kwayo okuxhaphakileyo malunga namashumi amahlanu eminyaka, iijini zokuxhathisa ezininzi ziye zavela ngoku, nto leyo eyenza ukuba i-clindamycin ingasebenzi kakuhle ngokuchasene neebhaktheriya ezininzi eluntwini. Kwakhona, akukho okunye antibiotic kweli qela labona ukukhanya kwemini phezu kwayo nje imigudu enzima kumashumi ambalwa eminyaka adluleyo.
Abaphandi basandul 'ukuxela i-chemical synthesis ye-Iboxamycin (IBX), inoveli ye-lincosamide efunyenwe isebenza kakhulu ngokuchasene ne-Gram-positive kunye ne-Gram-negative bacteria. in vitro kwaye kwi vivo izifundo zezilwanyana. Ngoyilo olusekwe kulwakhiwo kunye nolwakhiwo olusekwe kumacandelo, baphuhlise isikafula kwaye badibanisa loo nto kwintsalela ye-amino-octose ye-clindamycin. Isiphumo yi-Iboxamycin, i antibiotic efunyaniswe inamandla akhethekileyo ngokuchasene noluhlu olubanzi lweebhaktheriya ze-pathogenic kwizifundo zangaphambi kweklinikhi kwiimpuku. Ijolise kuhlobo lwasendle kunye nebhaktiriya exhathisayo kwaye ibonisa iziphumo ezinde ze-bacteriostatic emva kokuvezwa okufutshane.
Ukuphuhliswa kolu luhlu lubanzi antibiotic umviwa ubaluleke kakhulu kumaxesha angoku, xa esetyenziswa ngokuqhelekileyo antibiotics baye baphulukana nokuqaqamba ngenxa yenguquko ye-multiple drug-resistance (MDR), ebangelwa ikakhulu ngenxa yokusetyenziswa ngokungenamkhethe kweziyobisi. antibiotics, ngokwenza antibiotic ukuxhathisa kuyingozi enkulu kwimpilo yehlabathi.
Ukongeza, ngokungafaniyo ne-Lincomycin kunye ne-Clindamycin ezendalo kunye ne-semi-synthetic ngokulandelanayo, umgqatswa osanda kuphuhliswa i-Iboxamycin (IBX) yenziwe ngokupheleleyo, oko kuthetha ukuba ukufumaneka kwayo akunakuxhomekeke ngokupheleleyo kwimithombo yendalo, kwaye ngoko imveliso yayo yemizi-mveliso inokunyuswa ngokulula. ukuhlangabezana neemfuno eziphezulu. Kwakhona, ukuhlanganiswa kwee-analog ezininzi kunokwenzeka njengoko inkqubo isekelwe kwinxalenye. Obunye ubungqina bokusebenza kwayo kunye nokhuseleko buya kufumaneka emva kokuqalwa kolingo lwezonyango, oluya kwenzeka kuphela xa ishishini lamachiza libandakanyeka kwaye lifumana amalungelo elungelo elilodwa lomenzi wechiza kubavelisi, ukuze linyuke ngakumbi.
***
Imithombo:
- Mitcheltree, MJ, Pisipati, A., Syroegin, EA et al. Udidi lwe-antibiotics yokwenziwa eyoyisa ukunganyangeki kwebhaktiriya emininzi. Ipapashwe: 27 October 2021. Indalo (2021). DOI: https://doi.org/10.1038/s41586-021-04045-6
- Mason J., et al 2021. I-Practical Gram-Scale Synthesis ye-Iboxamycin, i-Antibiotic Candidate enamandla. J. Am. Ikhem. Soc. 2021, 143, 29, 11019-11025. Umhla wokupapashwa: Julayi 15, 2021. DOI: https://doi.org/10.1021/jacs.1c03529 Ifumaneka kwi ikhonkco
***
